Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ovarian Neoplasms

ClinicalTrials.gov lists 3,677 trials for Ovarian Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 190.

MeSH D010051 Neoplasms Neoplasm C04 C12 C19 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 832 Phase 1/2 Phase 1/2 362 Phase 2 Phase 2 933 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 277 Phase 4 Phase 4 35 Not applicable Not applicable 526 Observational Observational 674 Phase 1 Phase 1 832 Phase 1/2 Phase 1/2 362 Phase 2 Phase 2 933 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 277 Phase 4 Phase 4 35 Not applicable Not applicable 526 Observational Observational 674

Trials per phase (log scale)

1 more section with rows

3,249 of the 3,677 trials are tagged with Ovarian Neoplasms itself; the rest are tagged with a narrower condition beneath it.

Get the Ovarian Neoplasms report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ovarian Neoplasms trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 226

1990: 1 trials (Phase 1/2 1) 1991: 6 trials (Phase 3 1, Phase 2 3, Phase 1 2) 1992: 6 trials (Observational 3, Phase 2 1, Phase 1 2) 1993: 5 trials (Not applicable 1, Phase 2 4) 1994: 9 trials (Observational 2, Phase 3 1, Phase 1/2 2, Phase 1 4) 1995: 10 trials (Observational 3, Phase 3 2, Phase 2 5) 1996: 17 trials (Observational 2, Phase 3 6, Phase 2 3, Phase 1/2 1, Phase 1 5) 1997: 25 trials (Not applicable 2, Phase 3 2, Phase 2 10, Phase 1/2 4, Phase 1 7) 1998: 43 trials (Observational 2, Not applicable 2, Phase 3 8, Phase 2 20, Phase 1 11) 1999: 53 trials (Observational 8, Phase 3 11, Phase 2/3 1, Phase 2 21, Phase 1/2 2, Phase 1 10) 2000: 43 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2/3 1, Phase 2 14, Phase 1/2 4, Phase 1 14) 2001: 55 trials (Observational 5, Not applicable 4, Phase 4 1, Phase 3 5, Phase 2 23, Phase 1/2 3, Phase 1 14) 2002: 57 trials (Observational 8, Not applicable 6, Phase 4 1, Phase 3 8, Phase 2 22, Phase 1/2 3, Phase 1 9) 2003: 71 trials (Observational 9, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 34, Phase 1/2 7, Phase 1 12) 2004: 78 trials (Observational 7, Not applicable 10, Phase 4 1, Phase 3 6, Phase 2 31, Phase 1/2 5, Phase 1 18) 2005: 83 trials (Observational 11, Not applicable 7, Phase 3 7, Phase 2 35, Phase 1/2 7, Phase 1 16) 2006: 107 trials (Observational 19, Not applicable 9, Phase 3 5, Phase 2/3 4, Phase 2 47, Phase 1/2 6, Phase 1 17) 2007: 115 trials (Observational 20, Not applicable 4, Phase 3 8, Phase 2 46, Phase 1/2 8, Phase 1 29) 2008: 98 trials (Observational 14, Not applicable 8, Phase 4 1, Phase 3 8, Phase 2 37, Phase 1/2 7, Phase 1 23) 2009: 95 trials (Observational 17, Not applicable 9, Phase 3 11, Phase 2 29, Phase 1/2 11, Phase 1 18) 2010: 116 trials (Observational 16, Not applicable 18, Phase 3 5, Phase 2/3 2, Phase 2 42, Phase 1/2 9, Phase 1 24) 2011: 106 trials (Observational 20, Not applicable 9, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 25, Phase 1/2 7, Phase 1 36) 2012: 102 trials (Observational 21, Not applicable 15, Phase 4 1, Phase 3 8, Phase 2 23, Phase 1/2 16, Phase 1 18) 2013: 99 trials (Observational 22, Not applicable 10, Phase 4 2, Phase 3 9, Phase 2 26, Phase 1/2 6, Phase 1 24) 2014: 112 trials (Observational 15, Not applicable 28, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 18, Phase 1/2 14, Phase 1 31) 2015: 132 trials (Observational 25, Not applicable 25, Phase 3 9, Phase 2 30, Phase 1/2 10, Phase 1 33) 2016: 153 trials (Observational 35, Not applicable 27, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 30, Phase 1/2 17, Phase 1 34) 2017: 166 trials (Observational 34, Not applicable 26, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 31, Phase 1/2 21, Phase 1 44) 2018: 162 trials (Observational 23, Not applicable 25, Phase 4 6, Phase 3 17, Phase 2/3 1, Phase 2 40, Phase 1/2 15, Phase 1 35) 2019: 158 trials (Observational 33, Not applicable 18, Phase 4 2, Phase 3 17, Phase 2/3 1, Phase 2 25, Phase 1/2 15, Phase 1 47) 2020: 171 trials (Observational 38, Not applicable 32, Phase 4 3, Phase 3 14, Phase 2 31, Phase 1/2 18, Phase 1 35) 2021: 226 trials (Observational 45, Not applicable 43, Phase 4 1, Phase 3 15, Phase 2/3 1, Phase 2 38, Phase 1/2 29, Phase 1 54) 2022: 211 trials (Observational 55, Not applicable 38, Phase 4 2, Phase 3 12, Phase 2 39, Phase 1/2 18, Phase 1 47) 2023: 188 trials (Observational 35, Not applicable 45, Phase 4 2, Phase 3 4, Phase 2/3 4, Phase 2 38, Phase 1/2 25, Phase 1 35) 2024: 203 trials (Observational 54, Not applicable 24, Phase 4 1, Phase 3 7, Phase 2/3 4, Phase 2 44, Phase 1/2 20, Phase 1 49) 2025: 185 trials (Observational 39, Not applicable 34, Phase 4 2, Phase 3 17, Phase 2/3 2, Phase 2 29, Phase 1/2 28, Phase 1 34)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 177
2025 185
2024 203
2023 188
2022 211
2021 226
2020 171
2019 158
2018 162
2017 166

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 477 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 2,124 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ovarian Neoplasms trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 832
Phase 1/2 362
Phase 2 933
Phase 2/3 29
Phase 3 277
Phase 4 35
Not applicable 526
Observational 674
Expanded access 9

How many Ovarian Neoplasms trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 145
Recruiting 571
Enrolling by invitation 9
Active, not recruiting 244
Available 4

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ovarian Neoplasms trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 190
Gynecologic Oncology Group 77
AstraZeneca 63
Eli Lilly and Company 31
Pfizer 25

Which drugs are being tested for Ovarian Neoplasms? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
(nab)-paclitaxel 335
PEMBROLIZUMAB 103
TOPOTECAN 93
Cytoxan 90

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
or carboplatin 310
Bevacizumab 1 183
Gemcitabine/Gemzar 100
Cisplatin 1 89
Arm A - Olaparib 85

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ovarian Neoplasms trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Vomiting 1,196 249
Abdominal pain 953 199
Small intestinal obstruction 895 176
Nausea 887 234
Anaemia 878 138

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Ovarian Neoplasms? (2,397)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Impact of gated FDG PET/CT on the staging of patients with suspected or proven newly diagnosed advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer: results from a non-randomized, phase II clinical trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026 Yes
Multimodal prehabilitation improves functional capacity in patients with advanced ovarian cancer undergoing cytoreductive surgery. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026 Yes
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study. Annals of oncology : official journal of the European Society for Medical Oncology 2026 Yes
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial. Gynecologic oncology 2026 Yes
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes

Showing 5 of 2,397 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Rare ovarian cancer Point prevalence 1-5 / 10 000 Europe Not stated Unspecified
Rare ovarian cancer Point prevalence 1-5 / 10 000 Europe Not stated Exact
Rare ovarian cancer Point prevalence 1-5 / 10 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Rare ovarian cancer 213500 Exact Orphanet Rare Disease Ontology (ORDO)
Rare ovarian cancer 213500 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages